Adapter molecule crk (CRK) (CRK)

Adapter molecule crk (CRK) is a widely expressed adapter protein that consists primarily of Src homology 2 (SH2) and SH3 domains, which allow it to serve as a molecular bridge in various intracellular signaling pathways [1, 3]. It integrates signals from receptor tyrosine kinases and integrins, translating extracellular stimuli into cellular responses such as migration, proliferation, and survival [1, 4]. CRK is frequently overexpressed in several human malignancies, including lung, breast, and ovarian cancers, where it promotes tumor cell invasion and metastasis by modulating the actin cytoskeleton [3, 4]. The protein exists in two main isoforms, CRKI and CRKII, which are generated through alternative splicing and have distinct roles in signaling regulation [1]. Additionally, CRK is utilized by certain bacteria and viruses to facilitate host cell entry and infection, highlighting its importance in pathogenesis [2]. While no CRK-specific drugs are currently FDA-approved, research is focused on developing small molecules and peptidomimetics that block its SH2 or SH3 domains to inhibit oncogenic signaling [4]. These therapeutic efforts aim to disrupt the interaction between CRK and its binding partners like C3G or DOCK180, which are critical for activating Rho-family GTPases [3]. Targeting CRK presents a challenge due to its high sequence homology with other adapter proteins, necessitating high specificity to avoid off-target effects [4].

Other names

Proto-oncogene c-Crkp38CRKIICRKIv-crk avian sarcoma virus CT10 oncogene homolog

Competitive inhibition of SH2 or SH3 domain-mediated protein-protein interactions, which prevents the assembly of signaling complexes required for cell migration and proliferation.